Healhcare
INVESTORS, INC.

## Supplemental Information

Q4 2017

Omega Healthcare Investors, Inc. is a Real Estate Investment Trust ("REIT") providing financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities located in the United States.

As of December 31, 2017, Omega has a portfolio of investments that includes approximately 973 properties located in 41 states and the UK (53 facilities) and operated by 74 different operators (includes the Manhattan 2nd Avenue project).

As a source of capital to the healthcare industry, Omega continually evaluates the opportunities, trends and challenges affecting the industry. Our goal is to identify long-term investments in quality healthcare properties with outstanding operators that provide the most favorable risk/reward ratio to our investors.

## TABLE OF CONTENTS

## Portfolio

Investment Summary............................................... 3
Revenue Summary 3
Operator Payor Mix and Coverage Summary.. .....  3
Rent/Interest Concentration by Operator .....  .4
Lease and Mortgage Expirations .....  4
Diversification
Operator Geographic Diversification .....  .5
Selected Metrics
Occupancy by State. .....  5
EBITDARM \& EBITDAR Coverage Stratification .....  6
EBITDAR Coverages less than 1.0x .....  .6
Investment Activity .....  .7
New Builds, Major Renovations, \& Capex ..... 7
Capitalization
Capital Structure and Rates .....  8
Debt Maturity Schedule ..... 8
Senior Unsecured Debt Ratings .....  8
Selected Covenants and Ratios .....  9
Equity Issuance Summary ..... 10
Book and Market Capitalization ..... 11
Financial Performance
Historical AFFO, FAD and Dividends. ..... 12
Current Year Guidance ..... 13
Quarterly Financials
Income Statements ..... 14
Balance Sheets ..... 15
Statements of Cash Flow ..... 16
Non-GAAP Reconciliations
Net Income, FFO, Adjusted FFO and FAD ..... 17
EBITDA and Debt Coverage Ratios ..... 19
EBITDA and FC and Interest Coverage Ratios ..... 20
Selected Definitions ..... 21
Executive OfficersTaylor Pickett, President and Chief Executive OfficerDan Booth, Chief Operating OfficerSteven Insoft, Chief Corporate Development OfficerBob Stephenson, Chief Financial Officer
Mike Ritz, Chief Accounting Officer
Board of Directors
Craig R. Callen, Chairman
Craig M. Bernfield
Norman R. Bobins
Barbara B. Hill
Bernard J. Korman

## Analysts

| Bank of America/Merrill Lynch............ |  |  | Juan Sanabria... | 646-8 | 5-1589 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| BTIG. |  |  | Michael Gorman.. | 646-5 | 62-1320 |
| Cantor Fitzgerald. |  |  | Joseph France | 212-9 | 5-1239 |
| Capital One Securities......................... |  |  | Daniel Bernstein. | 571-83 | 35-7202 |
| Goldman Sachs. |  |  | Andrew Rosivach. | 212-9 | 2-2796 |
| Green Street Advisors......................... |  |  | Michael Knott | 949-6 | 40-8780 |
| Hilliard Lyons...................................... |  |  | John Roberts. | 502-5 | 88-1165 |
| Jefferies. |  |  | Tayo Okusanya.. | 212-33 | 36-7076 |
| JMP Securities. |  |  | Peter Martin. | 415-8 | 35-8900 |
| Stifel Nicolaus.. |  |  | Chad Vanacore. | 518-58 | 7-2581 |
| SunTrust. |  |  | Eric Fleming. | 617-3 | 45-6536 |
| UBS. |  |  | Nicholas Yulico....... | 212-7 | 3-3402 |
| Wells Fargo.. |  |  | Todd Stender.. | 212-21 | 14-8067 |
| Stock Symbol: | OHI | Shares \& Units Ou | standing December 31, | , 2017: | 207,080 |
| Exchange: | NYSE | CUSIP Number: |  |  | 6819 |

Edward Lowenthal
Stephen D. Plavin
Ben W. Perks
Taylor Pickett

## Contact Information

## Omega Healthcare Investors, Inc.

## 303 International Circle

 Suite 200Hunt Valley, MD 21030
(410) 427-1700 (Main)
(866) 996-6342 (Investor Relations)
www.omegahealthcare.com

Exchange: NYSE CUSIP Number: 681936100

Contan
$\qquad$

Transfer Agent Correspondence
Computershare, Inc.
P.O. Box 505000

Louisville, KY 40233
(800) 368-5948

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega's or its tenants', operators', borrowers' or managers' expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will" and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations. Omega does not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.

Omega's actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega's properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) regulatory and other changes in the healthcare sector; (iii) changes in the financial position of Omega's operators; (iv) the ability of any of Omega's operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega's mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; (v) the availability and cost of capital; (vi) changes in Omega's credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) Omega's ability to maintain its status as a REIT; (ix) Omega's ability to sell assets held for sale or complete potential asset sales on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (x) Omega's ability to re-lease, otherwise transition or sell underperforming assets on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) the potential impact of changes in the SNF and assisted living facility ("ALF") market or local real estate conditions on the Company's ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; (xiii) changes in interest rates; (xiv) changes in tax laws and regulations affecting REITs and (xv) other factors identified in Omega's filings with the Securities and Exchange Commission. Statements regarding future events and developments and Omega's future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements. Omega undertakes no obligation to update any forward-looking statements contained in this announcement.

Operator Information: This supplement includes information regarding the operators of our facilities such as EBITDAR and EBITDARM coverage ratios. The information related to operators that is provided in this supplement has been provided by the operators. We have not independently verified this information. We are providing this data for informational purposes only.

Non-GAAP Information: This supplement also contains certain non-GAAP financial information including EBITDA, Adjusted Total Debt (or Funded Debt), Adjusted Book Capitalization, FFO, Adjusted FFO, Funds Available for Distribution ("FAD"), Total Cash Fixed Charges and certain related ratios. A reconciliation of these non-GAAP disclosures is available in the Financial Performance section of this supplement.

Information is provided as of December 31, 2017, unless specifically stated otherwise. We assume no duty to update or supplement the information provided.

Investment Summary

| (\$ in thousands) | As of December 31, 2017 |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Balance Sheet Data | Total No. of Properties | Investment |  | \% of Investment | Total No. of Operating Properties ${ }^{(1)}$ | No. of Operating Beds |  |
| Real Estate Investments | 869 | \$ | 7,655,960 | 88\% | 881 | 88,007 |  |
| Direct Financing Leases | 41 |  | 364,965 | 4\% | 41 | 4,264 |  |
| Loans Receivable | 51 |  | 671,232 | 8\% | 51 | 5,366 |  |
|  | 961 | \$ | 8,692,157 | 100\% | 973 | 97,637 |  |
| Assets Held for Sale | 22 |  | 86,699 |  |  |  |  |
| Total Investments | 983 | \$ | 8,778,856 |  |  |  |  |
| Investment Data | Total No. of Properties |  | estment | $\%$ of Investment | Total No. of Operating Properties | No. of Operating Beds | Investment <br> Per Bed |
| Skilled Nursing/Transitional Care | 828 | \$ | 7,210,049 | 83\% | 844 | 89,646 | \$80 |
| Senior Housing ${ }^{(2)}$ | 133 |  | 1,482,108 | 17\% | 129 | 7,991 | \$185 |
|  | 961 | \$ | 8,692,157 | 100\% | 973 | 97,637 | \$89 |
| Assets Held for Sale | 22 |  | 86,699 |  |  |  |  |
| Total Investments | 983 | \$ | 8,778,856 |  |  |  |  |

1) Total \# of Operating Properties excludes facilities which are non-operating, closed and/or not currently providing patient services
2) Includes ALFs, memory care and independent living facilities

## Revenue Summary

(\$ in thousands)

| Revenue by Investment Type | Three Months Ended12/31/2017 |  |  | Twelve Months Ended 12/31/2017 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Rental Property | \$ | 194,579 | 88\% | \$ | 775,176 | 85\% |
| Direct Financing Leases |  | 614 | 0\% |  | 32,336 | 4\% |
| Mortgage Notes |  | 17,029 | 8\% |  | 66,202 | 7\% |
| Other Investment Income \& Misc Income - net |  | 8,984 | 4\% |  | 34,671 | 4\% |
|  | \$ | 221,206 | 100\% | \$ | 908,385 | 100\% |
| Revenue by Facility Type | Three Months Ended12/31/2017 |  |  | Twelve Months Ended12/31/2017 |  |  |
| Skilled Nursing / Transitional Care | \$ | 183,480 | 83\% | \$ | 765,736 | 84\% |
| Senior Housing |  | 28,742 | 13\% |  | 107,978 | 12\% |
| Other |  | 8,984 | 4\% |  | 34,671 | 4\% |
|  | \$ | 221,206 | 100\% | \$ | 908,385 | 100\% |

## Operator Payor Mix and Coverage Summary

| Three Months Ended... | \% Revenue Mix |  |  | Twelve Months Ended... | Occ. \% ${ }^{(1)}$ | Coverage Data |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Medicaid | Medicare / Insurance | Private / Other |  |  | EBITDARM | EBITDAR |
| September 30, 2017 | 52.9\% | 34.7\% | 12.4\% | September 30, 2017 | 82.2\% | 1.72x | 1.35x |
| June 30, 2017 | 51.9\% | 35.9\% | 12.2\% | June 30, 2017 | 82.4\% | 1.71x | 1.34x |
| March 31, 2017 | 51.0\% | 37.3\% | 11.7\% | March 31, 2017 | 82.5\% | 1.69x | 1.33x |
| December 31, 2016 | 52.6\% | 35.8\% | 11.6\% | December 31, 2016 | 82.2\% | 1.69x | 1.33x |
| September 30, 2016 | 53.0\% | 35.8\% | 11.2\% | September 30, 2016 | 82.1\% | 1.68x | 1.31x |

1) Based on available (operating) beds

## Rent/Interest Concentration by Operator

(\$ in thousands)

| Operator | $\begin{aligned} & \text { No. of }{ }^{(1)} \\ & \text { Properties } \end{aligned}$ | Total ${ }^{(2)}$ <br> Ann. Contractual Rent/Interest |  | \% of Total <br> Ann. Contractual Rent/Interest |
| :---: | :---: | :---: | :---: | :---: |
| 1 Ciena | 70 | \$ | 86,360 | 10.0\% |
| 2 Genesis | 50 |  | 59,588 | 6.9\% |
| 3 Signature | 60 |  | 56,738 | 6.6\% |
| 4 Communicare | 38 |  | 54,939 | 6.4\% |
| 5 Orianna | 42 |  | 46,591 | 5.4\% |
| 6 Saber | 44 |  | 40,741 | 4.7\% |
| 7 Maplewood | 14 |  | 35,831 | 4.1\% |
| 8 HHC | 44 |  | 35,234 | 4.1\% |
| 9 Guardian | 31 |  | 29,998 | 3.5\% |
| 10 Diversicare | 35 |  | 28,746 | 3.3\% |
| Remaining 64 Operators | 545 |  | 389,771 | 45.0\% |
|  | 973 | \$ | 864,537 | 100.0\% |

1) Number of Properties excludes facilities which are non-operating, closed and/or not currently providing patient services
2) $4 Q 2017$ annualized contractual rent/interest; includes mezzanine and term loan interest

## Lease and Mortgage Expirations

| (\$ in thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 4Q 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Year | Rent/Interest Annualized |  | \% | Lease |  | Capital Lease |  | Mortgage |  | Total |  | \% | No. | \% | No. | \% |
| 1 | 2018 | \$ | 10,458 | 1.2\% | \$ | 67,132 | \$ | - | \$ | 44,977 | \$ | 112,109 | 1.3\% | 17 | 1.7\% | 1,505 | 1.5\% |
| 2 | 2019 |  | 3,226 | 0.4\% |  | 19,408 |  | - |  | - |  | 19,408 | 0.2\% | 5 | 0.5\% | 308 | 0.3\% |
| 3 | 2020 |  | 12,644 | 1.5\% |  | 56,234 |  | 321 |  | 1,472 |  | 58,027 | 0.7\% | 10 | 1.0\% | 1,050 | 1.1\% |
| 4 | 2021 |  | 7,144 | 0.8\% |  | 93,718 |  | - |  | - |  | 93,718 | 1.1\% | 19 | 2.0\% | 576 | 0.6\% |
| 5 | 2022 |  | 64,738 | 7.5\% |  | 545,405 |  | - |  | - |  | 545,405 | 6.3\% | 79 | 8.1\% | 7,848 | 8.0\% |
| 6 | 2023 |  | 36,467 | 4.2\% |  | 288,682 |  | - |  | - |  | 288,682 | 3.3\% | 50 | 5.1\% | 4,613 | 4.7\% |
| 7 | 2024 |  | 59,657 | 6.9\% |  | 441,085 |  | - |  | 112,500 |  | 553,585 | 6.4\% | 53 | 5.4\% | 5,166 | 5.3\% |
| 8 | 2025 |  | 22,399 | 2.6\% |  | 177,690 |  | - |  | - |  | 177,690 | 2.0\% | 20 | 2.1\% | 2,605 | 2.7\% |
| 9 | 2026 |  | 19,729 | 2.3\% |  | 240,276 |  | - |  | - |  | 240,276 | 2.8\% | 23 | 2.4\% | 2,781 | 2.9\% |
| 10 | 2027 |  | 96,299 | 11.1\% |  | 1,183,399 |  | - |  | - |  | 1,183,399 | 13.6\% | 156 | 16.0\% | 13,651 | 14.0\% |
|  | Thereafter |  | 531,776 | 61.5\% |  | 4,542,931 |  | 364,644 |  | 512,283 |  | 5,419,858 | 62.3\% | 541 | 55.7\% | 57,534 | 58.9\% |
|  | TOTAL | \$ | 864,537 | 100.0\% | \$ | 7,655,960 | \$ | 364,965 | \$ | 671,232 | \$ | 8,692,157 | 100.0\% | 973 | 100.0\% | 97,637 | 100.0\% |

Note: All percentages rounded to one decimal



## Geographic Concentration by Investment

(\$ in thousands)

Texas
Florida
Ohio
Michigan
Indiana
California
Pennsylvania
Tennessee 40
North Carolina
Virginia
Remaining 31 states ${ }^{(3)}$
United Kingdom
Total
3) Includes New York City 2nd Avenue development project

| (\$ in thousands) | As of December 31, 2017 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { No. of } \\ \text { Properties } \end{gathered}$ | Investment ${ }^{(2)}$ |  | \% <br> Investment | $\begin{gathered} \% \\ \text { Occupancy }{ }^{(4)} \end{gathered}$ |
| Texas | 115 | \$ | 816,800 | 9.4\% | 70.7\% |
| Florida | 94 |  | 800,718 | 9.2\% | 88.0\% |
| Ohio | 73 |  | 712,614 | 8.2\% | 83.5\% |
| Michigan | 49 |  | 627,704 | 7.2\% | 85.0\% |
| Indiana | 65 |  | 582,818 | 6.7\% | 81.5\% |
| California | 54 |  | 496,985 | 5.7\% | 92.3\% |
| Pennsylvania | 43 |  | 470,145 | 5.4\% | 87.6\% |
| Tennessee | 40 |  | 331,053 | 3.8\% | 71.9\% |
| North Carolina | 32 |  | 268,975 | 3.1\% | 82.4\% |
| Virginia | 17 |  | 268,254 | 3.1\% | 82.4\% |
| Remaining 31 states ${ }^{(3)}$ | 326 |  | 2,908,610 | 33.5\% | 81.9\% |
|  | 908 | \$ | 8,284,676 | 95.3\% |  |
| United Kingdom | 53 |  | 407,481 | 4.7\% | 91.5\% |
| Total | 961 | \$ | 8,692,157 | 100.0\% | 82.2\% |

1) Excludes 22 properties classified as assets held for sale (AHS)
2) Excludes $\$ 86.7$ million (22 properties) classified as AHS
3) Includes New York City 2nd Avenue development project
4) As of September 30, 2017, TTM

Operator ebitdarm Coverage Distribution as a percentage of Rent/Debt Service—Based on 9/30/2017 TTM


Operator Ebitdar Coverage Distribution as a percentage of Rent/Debt Service—Based on 9/30/2017 TTM


NOTE: Core portfolio represents $83 \%$ of current rent/debt service which is representative of all stable properties. Stable properties include generally, any triple-net rental property unless it 1) is new development that is not yet complete/open; 2) has not yet stabilized and is still within 12 months following the budgeted stabilization date; 3 ) is held for sale and/or is slated for closure or to be sold; or 4) is slated to be transitioned or has transitioned to a new operator within the last 12 months.

## Master Leases with Operator EBITDAR Coverage < 1.0x

| - | EBITDARM Coverage | EBITDAR <br> Coverage | \% of Total Rent | Current on <br> Rent (1) | Subordinated Management Fees | Guaranty |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SNF/ALF | 0.21 | (0.05) | 0.3\% | $\checkmark$ |  | $\checkmark$ | $\checkmark$ |
| ALF | 0.69 | 0.58 | 0.7\% | $\checkmark$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| SNF | 1.16 | 0.94 | 0.4\% | $\checkmark$ | $\checkmark$ | $\checkmark$ |  |
| SNF | 1.36 | 0.95 | 0.7\% | $\checkmark$ |  | Limited | $\checkmark$ |
| Add'I 6 SNFs with EBITDAR Cov. <1.0 ${ }^{(2)}$ |  |  | 0.5\% | 5/6 | 0/6 | 6/6 | 6/6 |
|  |  |  | 2.6\% |  |  |  |  |

(1) Rent is current if < 30 days outstanding; measured on 2/9/18
(2) Combined EBITDARM Coverage is . $70 x$ and combined EBITDAR Coverage is $0.26 x$
(\$ in Thousands)
2012 Total Investments
2013 Total Investments
2014 Total Investments
2015 Total Investments

| 2016 |  |
| :---: | :---: |
| Acquisition | $1 / 18 / 2016$ |
| Acquisition | $2 / 1 / 2016$ |
| Acquisition | $3 / 1 / 2016$ |
| Acquisition | $3 / 15 / 2016$ |
| Acquisition | $3 / 1 / 2016$ |
| Acquisition | $4 / 1 / 2016$ |
| Acquisition | $4 / 20 / 2016$ |
| Acquisition | $4 / 29 / 2016$ |
| Acquisition | $7 / 29 / 2016$ |
| Acquisition | $8 / 31 / 2016$ |
| Acquisition | $8 / 31 / 2016$ |
| Acquisition | $9 / 30 / 2016$ |
| Acquisition | $9 / 30 / 2016$ |
| Acquisition | $9 / 30 / 2016$ |


| Total Acquisitions \& Mortgages | $\mathbf{\$ 1}$ | $\mathbf{9 7 0 , 1 1 0}$ |
| :--- | ---: | ---: |
| Construction-in-Progress |  | 62,197 |
| CAPEX Funding and Other |  | 72,515 |
| Mezz, Term Loans, DFL \& Other | $\mathbf{2 2 3 , 4 4 7}$ |  |
| $\mathbf{2 0 1 6}$ Total Investments | $\mathbf{1 , 3 2 8 , 2 6 9}$ |  |


| 2017 |  |  |  |
| :---: | :---: | :---: | :---: |
| Acquisition | 1/31/2017 | \$ | 7,574 |
| Acquisition | 5/8/2017 |  | 114,759 |
| Acquisition | 6/22/2017 |  | 8,644 |
| Mortgage | 6/30/2017 |  | 11,000 |
| Acquisition | 8/11/2017 |  | 2,294 |
| Acquisition | 8/31/2017 |  | 191,000 |
| Acquisition | 11/1/2017 |  | 39,974 |
| Total Acquisitions \& Mortgages |  | \$ | 375,246 |
| Construction-in-Progress |  |  | 78,432 |
| CAPEX Funding and Other |  |  | 59,424 |
| Direct Financing Leases \& Other |  |  | 16,625 |
| 2017 Total Investments |  | \$ | 529,727 |


| Investment <br> Amount |  |
| :---: | :---: |
| $\$$ | 509,558 |
| $\$$ | 620,858 |
| $\$$ | 565,510 |
| $\$$ | 506,944 |


| Facility Types |  |  |  |  |  |  |  | Totals |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SNF | Beds | ALF | Beds | Rehab | Beds | ILU | Units | Facilities | Beds/Uts |
| 39 | 4,832 | 6 | 601 | - | - | 6 | 259 | 51 | 5,692 |
| 59 | 5,769 | 2 | 152 | - | - | - | - | 61 | 5,921 |
| 25 | 2,684 | 7 | 541 | - | - | - | - | 32 | 3,225 |
| 12 | 1,367 | 27 | 1,212 | - | - | - | - | 39 | 2,579 |


|  |  |  |  |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| UK | - | - | 1 | 52 | - | - | - | - | 1 | 52 |
| MI, OH, VA | 10 | 985 | - | - | - | - | - | - | 10 | 985 |
| GA | - | - | 2 | 164 | - | - | - | - | 2 | 164 |
| UK | - | - | 1 | 33 | - | - | - | - | 1 | 33 |
| NC, VA | 21 | 2,446 | - | - | - | - | - | - | 21 | 2,446 |
| UK | - | - | 10 | 775 | - | - | - | - | 10 | 775 |
| TX | - | - | 3 | 367 | - | - | - | - | 3 | 367 |
| CO, MO | 3 | 338 | - | - | - | - | - | - | 3 | 338 |
| FL | - | - | 1 | 114 | - | - | - | - | 1 | 114 |
| FL | - | - | 1 | 175 | - | - | - | - | 1 | 175 |
| GA | - | - | 1 | 46 | - | - | - | - | 1 | 46 |
| SC | 1 | 144 | - | - | - | - | - | - | 1 | 144 |
| OH | 1 | 96 | - | - | - | - | - | - | 1 | 96 |
| FL, KY, TN | 31 | 4,047 | - | - | - | - | - | - | 31 | 4,047 |
|  | $\mathbf{6 7}$ | $\mathbf{8 , 0 5 6}$ | $\mathbf{2 0}$ | $\mathbf{1 , 7 2 6}$ | - | - | - | - | $\mathbf{8 7}$ | $\mathbf{9 , 7 8 2}$ |


| VA | - | - | 1 | 60 | - | - | - | - | 1 | 60 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| UK | - | - | 18 | 992 | - | - | - | - | 18 | 992 |
| NC | 1 | 100 | - | - | - | - | - | - | 1 | 100 |
| MI | 3 | 271 | - | - | - | - | - | - | 3 | 271 |
| TX | - | - | 1 | 48 | - | - | - | - | 1 | 48 |
| IN | 15 | 2,074 | - | - | - | - | - | - | 15 | 2,074 |
| TX | 6 | 573 | - | - | - | - | - | - | 6 | 573 |

## New Builds, Major Renovations and CAPEX Investments as of December 31, 2017


(1) Includes land and finance costs
(2) Inception to date funding multiplied by initial cash yield
(3) Current quarter revenue already reflects fundings to date

## Capital Structure

| Financial Instrument | Secured (Y/N) | $\begin{gathered} \text { Debt Capacity } \\ \text { in USD } \\ 12 / 31 / 2017 \\ \hline \end{gathered}$ | Month Ending Rate | Type | Latest <br> Maturity | Yrs to Maturity | Borrowed as of 12/31/2017 | \% of <br> Total | $\begin{aligned} & \text { 4Q } 2017 \\ & \text { Debt/Ann. } \\ & \text { EBITDA }^{(4)} \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Credit Facility: |  |  |  |  |  |  |  |  |  |
| Revolver - USD | N | 900,000,000 | 2.651\% | $\mathrm{V}^{(1)}$ | 5/25/22 ${ }^{(2)}$ | 4.4 Yrs | 290,000,000 | 6.3\% |  |
| Revolver - USD \& Alternate Currency | N | 350,000,000 | 2.651\% | $\mathrm{V}^{(1)}$ | $5 / 25 / 22^{(2)}$ | 4.4 Yrs | - | 0.0\% |  |
| \$425MM U.S Term Loan | N | 425,000,000 | 3.019\% | V | 5/25/22 | 4.4 Yrs | 425,000,000 | 9.2\% |  |
| \$100MM OHI LP Term Loan | N | 100,000,000 | 3.019\% | V | 5/25/22 | 4.4 Yrs | 100,000,000 | 2.2\% |  |
| £100MM Sterling Term Loan (3) | N | 135,130,000 | 1.941\% | V | 5/25/22 | 4.4 Yrs | 135,130,000 | 2.9\% |  |
| \$250MM Term | N | 250,000,000 | 3.800\% | F | 12/16/22 | 5.0 Yrs | 250,000,000 | 5.4\% |  |
| \$20M Sub-Notes | N | 20,000,000 | 9.000\% | F | 12/21/21 | 4.0 Yrs | 20,000,000 | 0.4\% |  |
| \$700M 4.375\% Notes | N | 700,000,000 | 4.375\% | F | 8/1/23 | 5.6 Yrs | 700,000,000 | 15.1\% |  |
| \$400M 4.95\% Notes | N | 400,000,000 | 4.950\% | F | 4/1/24 | 6.3 Yrs | 400,000,000 | 8.7\% |  |
| \$400M 4.50\% Notes | N | 400,000,000 | 4.500\% | F | 1/15/25 | 7.0 Yrs | 400,000,000 | 8.7\% |  |
| \$600M 5.25\% Notes | N | 600,000,000 | 5.250\% | F | 1/15/26 | 8.0 Yrs | 600,000,000 | 13.0\% |  |
| \$700M 4.50\% Notes | N | 700,000,000 | 4.500\% | F | 4/1/27 | 9.2 Yrs | 700,000,000 | 15.1\% |  |
| \$550M 4.75\% Notes | N | 550,000,000 | 4.750\% | F | 1/15/28 | 10.0 Yrs | 550,000,000 | 11.9\% |  |
| HUD (12 Loan Summary) | Y | 53,666,421 | 3.063\% | F | 7/1/44 | 26.5 Yrs | 53,666,421 | 1.2\% |  |
| Total Debt |  | \$ 5,583,796,421 |  |  |  |  | \$ 4,623,796,421 | 100.0\% | 5.29 x |
| Weighted Averages |  |  | 3.98\% |  |  | 7.1 Yrs | 4.25\% |  |  |
|  |  | Common Stock: $198,308,872$ shares at $\$ 27.54$ per share: |  |  |  |  | 5,461,426,335 |  |  |
|  |  | Operating Units: | 8,771, | 507 units | at \$27.54 per | unit: | 241,567,303 |  |  |

Total Market Capitalization $\quad \mathbf{\$ 1 0 , 3 2 6 , 7 9 0 , 0 5 9}$
Note: At December 31, 2017, Omega held approx. \$76MM of net cash and short-term investments (excludes UK balances)

1) Excludes $0.25 \%$ annual Facility Fee on the full commitment
2) Equivalent USD amount shown using exchange rate as of last day of month
3) Includes options for two, six-month extensions from 5/25/2021
4) See page 19 for details

## Debt Maturities



1) Mortgages guaranteed by HUD (excludes net deferred financing costs of $\$ 0.6$ million)
2) Reflected at $100 \%$ borrowing capacity; does not reflect extension options 3) $\$ 1.25$ billion excludes a $\$ 700$ million accordion feature and $\$ 6.0$ million net deferred financing costs. The $\$ 910$ million is comprised of a: $\$ 425$ million U.S. Dollar term loan, $£ 100$ million term loan (equivalent to $\$ 135.0$ million in US dollars), \$100 million term loan to Omega's operating partnership and \$250 million 2015 term loan (excludes $\$ 5.8$ million net deferred financing costs)
3) Excludes net discounts, deferred financing costs and a
\$1.5 million promissory note
4) Excludes $\$ 0.4$ million of fair market valuation adjustments

Senior Unsecured Credit Ratings

|  | CUSIP \# | Rating Information |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | S\&P | Moody's | Fitch |
| Common Stock | 681936100 |  |  |  |
| Senior Unsecured Debt |  |  |  |  |
| \$700M, 4.375\% 2023 Notes | 681936 BJ 8 | BBB- | Baa3 | BBB- |
| \$400M, 4.950\% 2024 Notes | 681936 BB 5 | BBB- | Baa3 | BBB- |
| \$400M, 4.500\% 2025 Notes | 681936 BD 1 | BBB- | Baa3 | BBB- |
| \$600M, 5.250\% 2026 Notes | 681936 BH 2 | BBB- | Baa3 | BBB- |
| \$700M, 4.500\% 2027 Notes | 681936 BF 6 | BBB- | Baa3 | BBB- |
| \$550M, 4.750\% 2028 Notes | 681936 BK 5 | BBB- | Baa3 | BBB- |
| Corporate Rating....................................................... |  | BBB- |  |  |
| Outlook.................................................................... |  | Stable | Stable | Stable |
| Analyst(s)... | ........ | Michael Souers | Lori Marks | Peter Siciliano |
|  |  | (212) 438-2508 | (212) 553-1098 | (646) 582-4760 |

## Selected Credit Facility and Unsecured Note Covenants ${ }^{(1)}$

## Credit Facility

|  | Consolidated |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Quarter Ending | Leverage <br> Ratio | Secured <br> Leverage <br> Ratio | Unsecured Leverage Ratio | Fixed Charge Cov. Ratio | Unsecured Interest Cov. Ratio | Current <br> Tangible Net Worth |
| Requirement | <= 60\% | <=30\% | <= 60\% | >=1.50 to 1 | >=2.00 to 1 | >\$3,399MM |
| March 30, 2017 | 46\% | 1\% | 50\% | 5.2 | 4.3 | Pass |
| June 30, 2017 | 52\% | 1\% | 54\% | 4.9 | 3.8 | Pass |
| September 30, 2017 | 54\% | 1\% | 55\% | 4.8 | 3.8 | Pass |
| December 31, 2017 | 51\% | 1\% | 53\% | 4.6 | 3.9 | Pass |
| Status | Pass | Pass | Pass | Pass | Pass | Pass |

## UNSECURED NOTES

|  | Unencumbered |  |  |
| :--- | :---: | :---: | :---: |
| Quarter Ending / Adj. | Assets / <br> Total Assets | Secured Debt / <br> Unsecured Debt | Adj. Total Assets |

(1) Covenants are based on calculations as defined in the Company's Credit Agreement and Senior Note Indentures

## Selected Credit Statistics

|  | 2017 |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 4Q | 3Q | 2Q | 1Q | 2016YE | 2015YE | 2014YE | 2013YE |
| Funded Debt / Adj. Pro Forma EBITDA ${ }^{(1)}$ | 5.1 | 5.1 | 4.8 | 4.7 | 4.7 | 4.5 | 4.6 | 4.4 |
| Secured Debt / Adjusted EBITDA ${ }^{(1)}$ | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.5 | 0.6 |
| Fixed Charge Coverage ${ }^{(2)}$ | 4.1 | 4.2 | 4.3 | 4.5 | 5.1 | 4.7 | 4.1 | 4.0 |
| Balance Sheet Cash (\$000) | 85,937 | 24,318 | 21,031 | 40,349 | 93,687 | 5,424 | 4,489 | 2,616 |

1) EBITDA is adjusted for non-cash and one-time items, and for leverage ratios includes proforma revenue for investments made in quarter/year; Total Net Funded Debt excludes outstanding L/C's, if any, premium on bonds, fair market valuations \& FIN46 consolidations and net of cash \& cash equivalents. EBITDA for "Qtr. Ending" periods are annualized
2) Fixed charges includes scheduled amortizations, amortization of deferred financing charges and capitalized interest

NOTE: See the Non-GAAP reconciliations provided at the end of this supplement and on our website at www.omegahealthcare.com under "Financial Information" then "Non-GAAP Financial Measures"

EQUITY ISSUANCE SUMMARY

## ESP/ATM Program

|  |  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Number of Shares (000s) |  | 3,398 |  | 6,504 |  | 1,848 |  | - |  | 656 |  | 718 |
| Average Price per Share | \$ | 23.47 | \$ | 30.48 | \$ | 34.33 | \$ | - | \$ | 31.10 | \$ | 32.14 |
| Gross Proceeds (000s) | \$ | 79,749 |  | 98,220 | \$ | 63,452 | \$ | - | \$ | 20,392 | \$ | 23,074 |

DRSPP and Waiver Program

|  |  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Number of Shares (000s) |  | 5,062 |  | 1,930 |  | 2,083 |  | 4,184 |  | 7,215 |  | 1,199 |
| Average Price per Share | \$ | 22.11 | \$ | 28.94 | \$ | 34.32 | \$ | 36.06 | \$ | 33.27 | \$ | 30.64 |
| Gross Proceeds (000s) | \$ 111,941 |  | \$ 55,872 |  | \$ 71,502 |  | \$ 150,871 |  | \$ 240,041 |  | \$ 36,722 |  |


| Secondary |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |  |
| Number of Shares (000s) |  | - |  | 2,875 |  | - |  | 10,925 |  | - |  | - |
| Average Price per Share | \$ | - | \$ | 29.48 | \$ | - | \$ | 42.00 | \$ | - | \$ | - |
| Gross Proceeds (000s) | \$ | - | \$ | 84,755 | \$ | - |  | 58,850 | \$ | - | \$ | - |

Totals

|  | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Number of Shares (000s) | 8,460 | 11,309 | 3,932 | 15,109 | 7,871 | 1,917 |
| Average Price per Share | \$ 22.66 | \$ 29.96 | \$ 34.32 | \$ 40.36 | \$ 33.09 | \$ 31.20 |
| Gross Proceeds (000s) | \$ 191,690 | \$ 338,847 | \$ 134,954 | \$ 609,721 | \$ 260,433 | \$ 59,796 |

Percentages of adjusted total debt to adjusted book capitalization and adjusted total debt to total market capitalization at December 31,2017 were $54.3 \%$ and $44.8 \%$, respectively. Adjusted total debt is total debt plus the discount or less the premium derived from the sale of unsecured borrowings, deferred financing costs (net) and fair market value adjustment of assumed debt. Adjusted book capitalization is defined as adjusted total debt plus stockholders' equity and noncontrolling interest. Adjusted total debt, adjusted book capitalization and related ratios are non-GAAP financial measures. Total market capitalization is the total market value of our securities as of December 31, 2017 plus adjusted total debt.

## Unaudited (In thousands)

|  | AtDecember 31, 2017 |  |
| :---: | :---: | :---: |
| Revolving line of credit.............................................................................. | \$ | 290,000 |
| Term loans.. |  | 910,130 |
| Secured borrowings. |  | 53,666 |
| Unsecured borrowings.. |  | 3,371,500 |
| FMV adjustment of assumption of debt |  | 375 |
| Premium/(discount) unsecured borrowings (net). |  | $(21,448)$ |
| Deferred financing costs (net). |  | $(32,065)$ |
| Total debt. | \$ | 4,572,158 |
| Deduct FMV adjustment of assumption of debt ......................................... |  | (375) |
| Add back discount (deduct premium) on unsecured borrowings (net).......... |  | 21,448 |
| Add back deferred financing costs (net). |  | 32,065 |
| Adjusted total debt. | \$ | 4,625,296 |
| BOOK CAPITALIZATION...................................................................... |  |  |
| Adjusted total debt.................................................................................. | \$ | 4,625,296 |
| Omega stockholders' equity. |  | 3,555,091 |
| Noncontrolling interest |  | 333,167 |
| Adjusted book capitalization. | \$ | 8,513,554 |
| MARKET CAPITALIZATION.................................................................. |  |  |
| Omega common shares and OP units outstanding at 12/31/2017.................. |  | 207,081 |
| Market price of common stock at 12/31/2017............................................. | \$ | 27.54 |
| Market capitalization of common stock at 12/31/2017............................. |  | 5,703,011 |
| Market capitalization of publicly traded securities. |  | 5,703,011 |
| Add adjusted total debt. |  | 4,625,296 |
| Total market capitalization. | \$ | 10,328,307 |
| Adjusted total debt / adjusted book capitalization................................... |  | 54.3\% |
| Adjusted total debt / total market capitalization...................................... |  | 44.8\% |


|  | Quarter Ended | Ending <br> Share <br> Price | Div. * <br> Yield | Quarterly |  |  |  |  |  | Omega AFFO Guidance ${ }^{(1)}$ | Annually |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | AFFO/ <br> Share |  | ividend | Payout <br> Ratio | FAD/ <br> Share | FAD <br> Payout <br> Ratio |  | AFFO/ <br> Share | $\%$ Change |  | FAD/ <br> Share | \% Change | Annual Dividend | \% Change |
| 2008 | 3/31/2008 | \$17.36 | 6.7\% | \$ 0.3639 | \$ | 0.30 | 82.4\% | \$0.3612 | 83.1\% | \$1.41-\$1.43 |  |  |  |  |  |  |  |
|  | 6/30/2008 | \$16.65 | 7.2\% | \$ 0.3816 |  | 0.30 | 78.6\% | \$0.3709 | 80.9\% |  |  |  |  |  |  |  |  |
|  | 9/30/2008 | \$19.66 | 6.1\% | \$0.3387 |  | 0.30 | 88.6\% | \$0.3079 | 97.4\% |  |  |  |  |  |  |  |  |
|  | 12/31/2008 | \$15.97 | 7.5\% | \$ 0.3702 |  | 0.30 | 81.0\% | \$0.3354 | 89.4\% |  | \$1.45 | 5.4\% |  | \$1.38 | 6.3\% | \$1.20 | 8.1\% |
| 2009 | 3/31/2009 | \$14.08 | 8.5\% | \$ 0.3701 | \$ | 0.30 | 81.1\% | \$0.3550 | 84.5\% | \$1.47-\$1.50 |  |  |  |  |  |  |  |
|  | 6/30/2009 | \$15.52 | 7.7\% | \$ 0.3714 |  | 0.30 | 80.8\% | \$0.3569 | 84.1\% |  |  |  |  |  |  |  |  |
|  | 9/30/2009 | \$16.02 | 7.5\% | \$ 0.3657 |  | 0.30 | 82.0\% | \$0.3529 | 85.0\% |  |  |  |  |  |  |  |  |
|  | 12/31/2009 | \$19.45 | 6.2\% | \$ 0.3604 |  | 0.32 | 88.8\% | \$0.3401 | 94.1\% |  | \$1.47 | 0.9\% |  | \$1.40 | 2.1\% | \$1.22 | 1.7\% |
| 2010 | 3/31/2010 | \$19.49 | 6.6\% | \$ 0.3766 | \$ | 0.32 | 85.0\% | \$0.3704 | 86.4\% | \$1.60-\$1.68 |  |  |  |  |  |  |  |
|  | 6/30/2010 | \$19.93 | 6.4\% | \$ 0.3652 |  | 0.36 | 98.6\% | \$0.3957 | 91.0\% |  |  |  |  |  |  |  |  |
|  | 9/30/2010 | \$22.45 | 6.4\% | \$0.4531 |  | 0.37 | 81.7\% | \$0.4218 | 87.7\% |  |  |  |  |  |  |  |  |
|  | 12/31/2010 | \$22.44 | 6.6\% | \$ 0.4566 |  | 0.37 | 81.0\% | \$0.4074 | 90.8\% |  | \$1.65 | 12.5\% |  | \$1.60 | 13.6\% | \$1.42 | 16.4\% |
| 2011 | 3/31/2011 | \$22.34 | 6.6\% | \$ 0.4432 | \$ | 0.38 | 85.7\% | \$0.4009 | 94.8\% | \$1.80-\$1.86 |  |  |  |  |  |  |  |
|  | 6/30/2011 | \$21.01 | 7.2\% | \$ 0.4748 |  | 0.40 | 84.2\% | \$0.4345 | 92.1\% |  |  |  |  |  |  |  |  |
|  | 9/30/2011 | \$15.93 | 10.0\% | \$ 0.4769 |  | 0.40 | 83.9\% | \$0.4392 | 91.1\% |  |  |  |  |  |  |  |  |
|  | 12/31/2011 | \$19.35 | 8.3\% | \$ 0.4963 |  | 0.41 | 82.6\% | \$0.4623 | 88.7\% |  | 1.89 | 14.5\% |  | \$1.74 | 8.9\% | \$1.59 | 12.0\% |
| 2012 | 3/31/2012 | \$21.26 | 7.7\% | \$ 0.5469 | \$ | 0.42 | 76.8\% | \$0.4738 | 88.6\% | \$2.06-\$2.12 |  |  |  |  |  |  |  |
|  | 6/30/2012 | \$22.50 | 7.5\% | \$ 0.5252 |  | 0.42 | 80.0\% | \$0.4535 | 92.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2012 | \$22.73 | 7.4\% | \$ 0.5353 |  | 0.44 | 82.2\% | \$0.4702 | 93.6\% |  |  |  |  |  |  |  |  |
|  | 12/31/2012 | \$23.85 | 7.4\% | \$ 0.5776 |  | 0.45 | 77.9\% | \$0.5236 | 85.9\% |  | \$ 2.18 | 15.3\% |  | \$1.92 | 10.6\% | \$1.73 | 8.8\% |
| 2013 | 3/31/2013 | \$30.36 | 5.9\% | \$ 0.6313 | \$ | 0.46 | 72.9\% | \$0.5739 | 80.2\% | \$2.45-\$2.50 |  |  |  |  |  |  |  |
|  | 6/30/2013 | \$31.02 | 5.9\% | \$ 0.6227 |  | 0.47 | 75.5\% | \$0.5614 | 83.7\% |  |  |  |  |  |  |  |  |
|  | 9/30/2013 | \$29.87 | 6.3\% | \$ 0.6260 |  | 0.48 | 76.7\% | \$0.5682 | 84.5\% |  |  |  |  |  |  |  |  |
|  | 12/31/2013 | \$29.80 | 6.4\% | \$ 0.6471 |  | 0.49 | 75.7\% | \$0.5861 | 83.6\% |  | \$2.53 | 15.9\% |  | \$2.29 | 19.2\% | \$1.90 | 9.8\% |
| 2014 | 3/31/2014 | \$33.52 | 5.8\% | \$ 0.7112 | \$ | 0.50 | 70.3\% | \$0.6506 | 76.9\% | \$2.69-\$2.72 |  |  |  |  |  |  |  |
|  | 6/30/2014 | \$36.86 | 5.4\% | \$ 0.6859 |  | 0.51 | 74.4\% | \$0.6257 | 81.5\% |  |  |  |  |  |  |  |  |
|  | 9/30/2014 | \$34.19 | 6.0\% | \$0.7320 |  | 0.52 | 71.0\% | \$0.6690 | 77.7\% |  |  |  |  |  |  |  |  |
|  | 12/31/2014 | \$39.07 | 5.3\% | \$0.7232 |  | 0.53 | 73.3\% | \$0.6621 | 80.0\% |  | \$2.85 | 12.9\% | \$ | 2.61 | 13.9\% | \$2.06 | 8.4\% |
| 2015 | 3/31/2015 | \$40.57 | 5.2\% | \$ 0.7084 | \$ | 0.54 | 76.2\% | \$0.6492 | 83.2\% | \$2.98-\$3.04 |  |  |  |  |  |  |  |
|  | 6/30/2015 | \$34.33 | 6.3\% | \$ 0.7696 |  | 0.55 | 71.5\% | \$0.7000 | 78.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2015 | \$35.15 | 6.3\% | \$ 0.7913 |  | 0.56 | 70.8\% | \$0.7168 | 78.1\% |  |  |  |  |  |  |  |  |
|  | 12/31/2015 | \$34.98 | 6.4\% | \$ 0.8067 |  | 0.57 | 70.7\% | \$0.7237 | 78.8\% |  | \$3.08 | 7.8\% | \$ | 2.79 | 7.0\% | \$2.22 | 7.8\% |
| 2016 | 3/31/2016 | \$35.30 | 6.5\% | \$ 0.8336 | \$ | 0.58 | 69.6\% | \$0.7488 | 77.5\% | \$3.25-\$3.30 |  |  |  |  |  |  |  |
|  | 6/30/2016 | \$33.95 | 6.8\% | \$ 0.8684 |  | 0.60 | 69.1\% | \$0.7731 | 77.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2016 | \$35.45 | 6.8\% | \$ 0.8327 |  | 0.61 | 73.3\% | \$0.7477 | 81.6\% |  |  |  |  |  |  |  |  |
|  | 12/31/2016 | \$31.26 | 7.8\% | \$ 0.8803 |  | 0.62 | 70.4\% | \$0.7965 | 77.8\% |  | \$3.42 | 11.0\% | \$ | 3.07 | 9.9\% | \$2.41 | 8.6\% |
| 2017 | 3/31/2017 | \$32.99 | 7.5\% | \$ 0.8569 | \$ | 0.63 | 73.5\% | \$0.7730 | 81.5\% | \$3.40-\$3.44 |  |  |  |  |  |  |  |
|  | 6/30/2017 | \$33.02 | 7.6\% | \$ 0.8661 |  | 0.64 | 73.9\% | \$0.7838 | 81.7\% |  |  |  |  |  |  |  |  |
|  | 9/30/2017 | \$31.91 | 8.0\% | \$ 0.7918 |  | 0.65 | 82.1\% | \$0.7285 | 89.2\% |  |  |  |  |  |  |  |  |
|  | 12/31/2017 | \$27.54 | 9.4\% | \$ 0.7882 |  | 0.66 | 83.7\% | \$0.7178 | 91.9\% |  | \$3.30 | -3.3\% | \$ | 3.00 | -2.1\% | \$2.58 | 7.1\% |

* Based on the annualized dividend announced the previous quarter

1) Guidance provided at the beginning of each fiscal year and does not reflect mid-year guidance changes.

No. of consecutive quarterly dividends paid since 2003: 58
No. of quarterly dividend increases since 2003:
No. of consecutive quarterly dividend increases:

| Revised 2018 Guidance: | AFFO: | \$2.96-\$3.06 |
| :---: | :---: | :---: |
|  | FAD: | \$2.64-\$2.74 |

NOTE: See the Non-GAAP reconciliations provided at the end of this supplement and on our website at www.omegahealthcare.com under "Financial Information" then "Non-GAAP Financial Measures"

## 2018 FFO, Adjusted FFO and FAD Guidance and Reconciliation

The Company currently expects its 2018 Adjusted FFO to be between $\$ 2.96$ and $\$ 3.06$ per diluted share and its 2018 FAD guidance to be between $\$ 2.64$ and $\$ 2.74$ per diluted share. The following table presents a reconciliation of Omega's guidance regarding FFO, Adjusted FFO and FAD to projected GAAP earnings.

## 2018 Annual FFO, Adjusted FFO and FAD Guidance Range ${ }^{(1)}$

|  | Full Year |
| :---: | :---: |
| Net Income............................................. | \$1.43-\$1.53 |
| Depreciation........................................ | 1.45 |
| Gain on assets sold................................ | - |
| Real estate impairment.......................... | - |
| FFO................................................... | \$2.88-\$2.98 |
| Adjustments: |  |
| Acquisition/transaction costs.................. | - |
| Interest - refinancing costs..................... | - |
| Stock-based compensation expense........ | 0.08 |
| Adjusted FFO....................................... | \$2.96-\$3.06 |
| Non-cash interest expense........................ | 0.04 |
| Capitalized interest.................................. | (0.04) |
| Non-cash revenue. | (0.32) |
| FAD................................................... | \$2.64-\$2.74 |

## Note: All per share numbers rounded to two decimals.

1) The Company's Adjusted FFO guidance for 2018 reflects the impact of approximately $\$ 100$ million of planned capital renovation projects, the sale of $\$ 87$ million of assets held for sale, approximately $\$ 300$ million of potential divestitures and the redeployment of capital from asset sales. It assumes the Company will not be recording revenue related to its Orianna portfolio for the majority of 2018. It also excludes the impact of gains and losses from the sale of assets, certain revenue and expense items, interest refinancing expense, capital transactions, acquisition costs, and additional provision for uncollectible accounts, if any. The Company may, from time to time, update its publicly announced Adjusted FFO guidance, but it is not obligated to do so.

The Company's guidance is based on a number of assumptions, which are subject to change and many of which are outside the Company's control. If actual results vary from these assumptions, the Company's expectations may change. Without limiting the generality of the foregoing, the timing and completion of acquisitions, divestitures, capital and financing transactions, and variations in stock-based compensation expense may cause actual results to vary materially from our current expectations. There can be no assurance that the Company will achieve its projected results.

Unaudited (in thousands, except per share amounts)

|  | Three Months Ended December 31, |  |  |  | Twelve Months Ended December 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| Revenue |  |  |  |  |  |  |  |  |
| Rental income | \$ | 194,579 | \$ | 194,891 | \$ | 775,176 | \$ | 743,885 |
| Income from direct financing leases |  | 614 |  | 15,724 |  | 32,336 |  | 62,298 |
| Mortgage interest income |  | 17,029 |  | 15,838 |  | 66,202 |  | 69,811 |
| Other investment income - net |  | 7,788 |  | 7,210 |  | 29,225 |  | 21,852 |
| Miscellaneous income |  | 1,196 |  | 823 |  | 5,446 |  | 2,981 |
| Total operating revenues |  | 221,206 |  | 234,486 |  | 908,385 |  | 900,827 |
| Expenses |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  | 75,323 |  | 70,808 |  | 287,591 |  | 267,062 |
| General and administrative |  | 8,218 |  | 74,786 |  | 32,471 |  | 32,077 |
| Stock-based compensation .................................................... |  | 3,862 |  | 3,674 |  | 15,212 |  | 13,790 |
| Acquisition costs |  | - |  | - |  | - |  | 9,582 |
| Impairment loss on real estate properties |  | 63,460 |  | - |  | 99,070 |  | 58,726 |
| Impairment on direct financing leases ..................................... |  | 231 |  | - |  | 198,199 |  | - |
| Provision for uncollectible accounts |  | 913 |  | 5,878 |  | 14,580 |  | 9,845 |
| Total operating expenses ......................................................... |  | 152,007 |  | 87,836 |  | 647,123 |  | 391,082 |
| Income before other income and expense .................................. |  | 69,199 |  | 146,650 |  | 261,262 |  | 509,745 |
| Other income (expense) |  |  |  |  |  |  |  |  |
| Interest income |  | 5 |  | 4 |  | 267 |  | 173 |
| Interest expense |  | $(48,253)$ |  | $(44,375)$ |  | $(188,762)$ |  | $(164,103)$ |
| Interest - amortization of deferred financing costs .................... |  | $(2,243)$ |  | $(2,501)$ |  | $(9,516)$ |  | $(9,345)$ |
| Interest - refinancing costs |  | - |  | - |  | $(21,965)$ |  | $(2,113)$ |
| Contractual settlement |  | - |  | - |  | 10,412 |  | - |
| Realized gain (loss) on foreign exchange |  | 76 |  | 12 |  | 311 |  | (232) |
| Total other expense ................................................................. |  | $(50,415)$ |  | $(46,860)$ |  | $(209,253)$ |  | $(175,620)$ |
| Income before gain on assets sold ............................................. |  | 18,784 |  | 99,790 |  | 52,009 |  | 334,125 |
| Gain on assets sold - net |  | 46,421 |  | 30,277 |  | 53,912 |  | 50,208 |
| Income from continuing operations .......................................... |  | 65,205 |  | 130,067 |  | 105,921 |  | 384,333 |
| Income tax expense. |  | (558) |  | (623) |  | $(3,248)$ |  | $(1,405)$ |
| Income from unconsolidated joint venture .............................. |  | 509 |  | 439 |  | 2,237 |  | 439 |
| Net income. |  | 65,156 |  | 129,883 |  | 104,910 |  | 383,367 |
| Net income attributable to noncontrolling interest ...................... |  | $(2,756)$ |  | $(5,624)$ |  | $(4,491)$ |  | $(16,952)$ |
| Net income available to common stockholders | \$ | 62,400 | \$ | 124,259 | \$ | 100,419 | \$ | 366,415 |

Income per common share available to common stockholders:
Basic:


| \$ | 0.51 | \$ | 1.91 |
| :---: | :---: | :---: | :---: |
| \$ | 0.51 | \$ | 1.90 |
| \$ | 2.54 | \$ | 2.36 |
|  | 197,738 |  | 191,781 |
|  | 206,790 |  | 201,635 |

(in thousands)

|  | December 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  |
|  | (Unaudited) |  |  |  |
| ASSETS |  |  |  |  |
| Real estate properties |  |  |  |  |
| Real estate investments | \$ | 7,655,960 | \$ | 7,566,358 |
| Less accumulated depreciation |  | $(1,376,828)$ |  | $(1,240,336)$ |
| Real estate investments - net |  | 6,279,132 |  | 6,326,022 |
| Investments in direct financing leases - net |  | 364,965 |  | 601,938 |
| Mortgage notes receivable - net |  | 671,232 |  | 639,343 |
|  |  | 7,315,329 |  | 7,567,303 |
| Other investments - net |  | 276,342 |  | 256,846 |
| Investment in unconsolidated joint venture ....................................... |  | 36,516 |  | 48,776 |
| Assets held for sale - net |  | 86,699 |  | 52,868 |
| Total investments |  | 7,714,886 |  | 7,925,793 |
| Cash and cash equivalents |  | 85,937 |  | 93,687 |
| Restricted cash |  | 10,871 |  | 13,589 |
| Accounts receivable - net |  | 279,334 |  | 240,035 |
| Goodwill |  | 644,690 |  | 643,474 |
| Other assets |  | 37,587 |  | 32,682 |
| Total assets | \$ | 8,773,305 | \$ | 8,949,260 |
| LIABILITIES AND EQUITY |  |  |  |  |
| Revolving line of credit ...................................................................... | \$ | 290,000 | \$ | 190,000 |
| Term loans - net |  | 904,670 |  | 1,094,343 |
| Secured borrowings - net . |  | 53,098 |  | 54,365 |
| Unsecured borrowings - net |  | 3,324,390 |  | 3,028,146 |
| Accrued expenses and other liabilities |  | 295,142 |  | 360,514 |
| Deferred income taxes |  | 17,747 |  | 9,906 |
| Total liabilities ............................................................................ |  | 4,885,047 |  | 4,737,274 |

Equity:
Common stock $\$ .10$ par value authorized - 350,000 shares, issued and outstanding - 198,309 shares as of December 31, 2017 and 196,142 as of December 31, 2016.........................................

| 19,831 | 19,614 |
| ---: | ---: |
| $4,936,302$ | $4,861,408$ |
| $1,839,356$ | $1,738,937$ |
|  | $(3,210,248)$ |
| $(30,150)$ | $(2,707,387)$ |
| $3,555,091$ | $3,85,827)$ |
| 333,167 | 353,241 |
| $3,888,258$ | $4,211,986$ |
| $\$ 3,773,305$ | $\$$ |

## 2017 Unaudited (in thousands)

|  | Year Ended December 31, |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2015 |  |
| Cash flows from operating activities |  |  |  |  |  |  |
| Net income | \$ | 104,910 | \$ | 383,367 | \$ | 233,315 |
| Adjustment to reconcile net income to net cash provided by operating activities:.... |  |  |  |  |  |  |
| Depreciation and amortization |  | 287,591 |  | 267,062 |  | 210,703 |
| Impairment loss on real estate properties |  | 99,070 |  | 58,726 |  | 17,681 |
| Impairment loss on direct financing leases. |  | 198,199 |  | - |  | - |
| Provision for uncollectible accounts |  | 14,580 |  | 9,845 |  | 7,871 |
| Refinancing costs and amortization of deferred financing costs .......................... |  | 19,711 |  | 11,458 |  | 35,827 |
| Accretion of direct financing leases. |  | $(6,107)$ |  | $(12,157)$ |  | $(11,007)$ |
| Stock-based compensation expense .............................................................. |  | 15,212 |  | 13,790 |  | 11,133 |
| Gain on assets sold - net |  | $(53,912)$ |  | $(50,208)$ |  | $(6,353)$ |
| Amortization of acquired in-place leases - net |  | $(11,910)$ |  | $(13,991)$ |  | $(13,846)$ |
| Effective yield receivable on mortgage notes |  | $(1,924)$ |  | (721) |  | $(4,065)$ |
| Change in operating assets and liabilities - net of amounts assumed/acquired: |  |  |  |  |  |  |
| Contractual receivables |  | $(36,621)$ |  | $(4,876)$ |  | 248 |
| Straight-line rent receivables |  | $(25,240)$ |  | $(42,091)$ |  | $(36,057)$ |
| Lease inducements |  | $(8,419)$ |  | 2,589 |  | 994 |
| Other operating assets and liabilities |  | $(17,228)$ |  | 1,980 |  | 2,972 |
| Net cash provided by operating activities |  | 577,912 |  | 624,773 |  | 449,416 |
| Cash flows from investing activities |  |  |  |  |  |  |
| Acquisition of real estate - net of liabilities assumed and escrows acquired ................ |  | $(385,418)$ |  | $(959,748)$ |  | $(294,182)$ |
| Cash acquired in acquisition/merger |  | 2,341 |  | - |  | 84,858 |
| Investments in construction in progress |  | $(86,689)$ |  | $(68,983)$ |  | $(164,226)$ |
| Investments in direct financing leases |  | $(7,183)$ |  | $(2,080)$ |  | $(6,793)$ |
| Proceeds from sale of direct financing lease assets |  | 33,306 |  | - |  | - |
| Placement of mortgage loans |  | $(34,643)$ |  | $(48,722)$ |  | $(14,042)$ |
| Investments in unconsolidated joint venture |  | - |  | $(50,032)$ |  | - |
| Distributions from unconsolidated joint venture |  | 12,175 |  | 1,318 |  | - |
| Proceeds from sale of real estate investments |  | 257,812 |  | 169,603 |  | 41,543 |
| Capital improvements to real estate investments |  | $(37,766)$ |  | $(40,471)$ |  | $(26,397)$ |
| Receipts from insurance proceeds |  | 2,754 |  | - |  | - |
| Proceeds from other investments |  | 95,696 |  | 96,789 |  | 45,871 |
| Investments in other investments |  | $(139,047)$ |  | $(271,557)$ |  | $(65,402)$ |
| Collection of mortgage principal |  | 1,529 |  | 59,975 |  | 1,359 |
| Net cash used in investing activities |  | $(285,133)$ |  | $(1,113,908)$ |  | $(397,411)$ |
| Cash flows from financing activities |  |  |  |  |  |  |
| Proceeds from credit facility borrowings |  | 1,687,000 |  | 1,304,000 |  | 1,826,000 |
| Payments on credit facility borrowings |  | $(1,587,000)$ |  | $(1,344,000)$ |  | $(1,681,000)$ |
| Receipts of other long-term borrowings |  | 1,346,749 |  | 1,048,173 |  | 1,838,124 |
| Payments of other long-term borrowings |  | $(1,252,788)$ |  | $(181,249)$ |  | $(2,187,314)$ |
| Payments of financing related costs. |  | $(29,198)$ |  | $(11,830)$ |  | $(54,721)$ |
| Receipts from dividend reinvestment plan |  | 36,722 |  | 240,041 |  | 150,847 |
| Payments for exercised options and restricted stock |  | $(2,143)$ |  | $(23,426)$ |  | $(26,706)$ |
| Net proceeds from issuance of common stock |  | 22,120 |  | 19,651 |  | 439,322 |
| Dividends paid |  | $(502,603)$ |  | $(453,152)$ |  | $(358,232)$ |
| Redemption of Omega OP Units |  | (48) |  | (733) |  | - |
| Distributions to Omega OP Unit Holders |  | $(22,626)$ |  | $(21,179)$ |  | $(11,636)$ |
| Net cash (used in) provided by financing activities |  | $(303,815)$ |  | 576,296 |  | $(65,316)$ |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash .... |  | 568 |  | 84 |  | (223) |
| (Decrease) increase in cash, cash equivalents, and restricted cash ............................ |  | $(10,468)$ |  | 87,245 |  | $(13,534)$ |
| Cash, cash equivalents, and restricted cash at beginning of year |  | 107,276 |  | 20,031 |  | 33,565 |
| Cash, cash equivalents, and restricted cash at end of year ...... | \$ | 96,808 | \$ | 107,276 | \$ | 20,031 |

# Net Income, FFO, Adjusted FFO and FAD <br> (unaudited) 

(in thousands, except per share data)

|  | Three Months Ended December 31, |  |  |  | Twelve Months Ended December 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| Net income ......................................................................................... | \$ | 65,156 | \$ | $129,883$ | \$ | $104,910$ | \$ | $383,367$ |
| Deduct gain from real estate dispositions. |  | $(46,421)$ |  | $(30,277)$ |  | $(53,912)$ |  | $(50,208)$ |
| Sub - total |  | 18,735 |  | 99,606 |  | 50,998 |  | 333,159 |
| Elimination of non-cash items included in net income: |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  | 75,323 |  | 70,808 |  | 287,591 |  | 267,062 |
| Depreciation - unconsolidated joint venture .................................... |  | 1,657 |  | 1,107 |  | 6,630 |  | 1,107 |
| Add back non-cash provision for impairments on real |  | 63,460 |  | - |  | 99,070 |  | 58,726 |
| Funds from operations ("FFO") ........................................................ | \$ | 159,175 | \$ | 171,521 | \$ | 444,289 | \$ | 660,054 |
| Weighted-average common shares outstanding, basic ........................... |  | 198,614 |  | 195,793 |  | 197,738 |  | 191,781 |
| Restricted stock and PRSUs ........................................................ |  | 260 |  | 300 |  | 269 |  | 956 |
| Omega OP Units |  | 8,772 |  | 8,862 |  | 8,783 |  | 8,898 |
| Weighted-average common shares outstanding, diluted |  | 207,646 |  | 204,955 |  | 206,790 |  | 201,635 |
| Funds from operations available per share ....................................... | \$ | 0.77 | \$ | 0.84 | \$ | 2.15 | \$ | 3.27 |
| Adjustments to calculate adjusted funds from operations:.................. |  |  |  |  |  |  |  |  |
| Funds from operations stockholders ................................................. | \$ | 159,175 | \$ | 171,521 | \$ | 444,289 | \$ | 660,054 |
| Deduct other revenue ................................................................... |  | (513) |  | (650) |  | $(2,394)$ |  | $(1,333)$ |
| Deduct prepayment fee income from early termination of mortgages ...... |  | - |  | - |  | - |  | $(5,390)$ |
| Deduct contractual settlement ......................................................... |  | - |  | - |  | $(10,412)$ |  | - |
| (Deduct)/add back acquisition costs ................................................ |  | - |  | (2) |  | (22) |  | 9,582 |
| Add back impairment for direct financing leases ................................. |  | 231 |  | - |  | 198,199 |  | - |
| Add back provision for uncollectible accounts ................................... |  | 913 |  | 5,878 |  | 14,580 |  | 9,845 |
| Add back interest refinancing expense |  | - |  | - |  | 23,539 |  | 2,113 |
| Add back non-cash stock-based compensation expense |  | 3,862 |  | 3,674 |  | 15,212 |  | 13,790 |
| Adjusted funds from operations ("Adjusted FFO") ........................... | \$ | 163,668 | \$ | 180,421 | \$ | 682,991 | \$ | 688,661 |
| Adjustments to calculate funds available for distribution: ................. |  |  |  |  |  |  |  |  |
| Non-cash interest expense .............................................................. |  | 2,215 |  | 2,920 |  | 10,076 |  | 9,754 |
| Capitalized interest ....................................................................... |  | $(2,124)$ |  | $(1,829)$ |  | $(7,991)$ |  | $(6,594)$ |
| Non-cash revenues ........................................................................ |  | $(14,718)$ |  | $(18,274)$ |  | $(64,117)$ |  | $(73,500)$ |
| Funds available for distribution ("FAD") ......................................... | \$ | 149,041 | \$ | 163,238 | \$ | 620,959 | \$ | 618,321 |

Funds From Operations ("FFO"), Adjusted FFO and Funds Available for Distribution ("FAD") are non-GAAP financial measures. For purposes of the Securities and Exchange Commission's Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts ("NAREIT"), and consequently, FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. The Company believes that FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term FFO was designed by the real estate industry to address this issue. FFO described herein is not necessarily comparable to FFO of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above. FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company's core portfolio as a REIT. The Company's computation of Adjusted FFO and FAD are not comparable to the NAREIT definition of FFO or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses Adjusted FFO among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO can facilitate comparisons of operating performance between periods and between other REITs. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company's securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.
For information regarding Adjusted Total Debt and Adjusted Book Capitalization, see the "Capitalization: Book and Market Capitalization with Ratios" section of this supplement.

## EBITDA Reconciliation and Debt Coverage Ratio Calculation

Our ratios of Funded Debt to annualized EBITDA, adjusted annualized EBITDA and Funded Debt to adjusted pro forma annualized EBITDA as of December 31, 2017 were $5.87 x, 5.29 x$ and $5.13 x$, respectively. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA eliminates items such as acquisition costs and stock-based compensation expense and adds back certain non-cash expenses, if any, to EBITDA. Adjusted pro forma EBITDA adds to adjusted EBITDA the incremental EBITDA from (i) new investments and divestitures made during the 4th quarter assuming an October 1st purchase or sale date, (ii) inception to date funding of construction in progress multiplied by the estimated contractual quarterly yield assuming an October 1st in-service date and (iii) revenue from Daybreak (see footnote 2). EBITDA, adjusted EBITDA, adjusted pro forma EBITDA and related ratios are non-GAAP financial measures. Annualized EBITDA, adjusted annualized EBITDA and adjusted pro forma annualized EBITDA assume the current quarter results multiplied by four, and are not projections of future performance. Below is the reconciliation of EBITDA and adjusted EBITDA to net income.

| Unaudited (In thousands) |  | ths Ended $\text { r 31, } 2017$ |
| :---: | :---: | :---: |
| Net income. | \$ | 65,156 |
| Depreciation and amortization. |  | 75,323 |
| Depreciation - unconsolidated joint venture |  | 1,657 |
| Interest - net. |  | 50,491 |
| Income taxes. |  | 558 |
| EBITDA. | \$ | 193,185 |
| Deduct gain on assets sold - net |  | $(46,421)$ |
| Deduct foreign currency gain.. |  | (76) |
| Deduct one-time revenue. |  | (513) |
| Add back non-cash impairment on direct financing leases. |  | 231 |
| Add back non-cash provision for uncollectible accounts. |  | 913 |
| Add back non-cash provision for impairments on real estate properties. |  | 63,460 |
| Add back stock-based compensation expense. |  | 3,862 |
| Adjusted EBITDA. | \$ | 214,641 |
| Add incremental pro forma EBITDA from new investments in Q4 |  | 461 |
| Add incremental pro forma EBITDA from construction in progress through Q4.. |  | 3,998 |
| Add incremental revenue/EBITDA from Daybreak. |  | 7,146 |
| Deduct incremental pro forma revenue from Q4 asset divestitures |  | $(5,052)$ |
| Adjusted pro forma EBITDA.. | \$ | 221,194 |
| DEBT |  |  |
| Revolving line of credit. | \$ | 290,000 |
| Term loans.. |  | 910,130 |
| Secured borrowings |  | 53,666 |
| Unsecured borrowings. |  | 3,371,500 |
| FMV adjustment of assumption of debt |  | 375 |
| Premium/(discount) on unsecured borrowings - net. |  | $(21,448)$ |
| Deferred financing costs - net. |  | $(32,065)$ |
| Total debt. | \$ | 4,572,158 |
| Deduct balance sheet cash and cash equivalents. |  | $(85,937)$ |
| Net total debt. | \$ | 4,486,221 |
| Deduct FMV adjustment for assumption of debt |  | (375) |
| Add back discount (deduct premium) on unsecured borrowings - net. |  | 21,448 |
| Add back deferred financing costs - net. |  | 32,065 |
| Adjusted total debt (a/k/a Funded Debt). | \$ | 4,539,359 |
| Funded Debt / annualized EBITDA .............................................................................. |  | 5.87 x |
| Funded Debt / adjusted annualized EBITDA ................................................................... |  | 5.29 x |
| Funded Debt / adjusted pro forma annualized EBITDA...................................................... |  | 5.13 x |

(1) Used to calculate leverage only.
(2) Placed Daybreak on a cash basis effective September 1, 2017 and recorded no revenue in the three months ended December 31, 2017. Monthly contractual rent is currently being paid; however, payments will not be recorded as revenue until 2017 outstanding receivables are fully repaid --anticipated early 2018.
NOTE: Assuming the Orianna facilities generate $\$ 32$ million of annual rent or rent equivalents post-transition (or the low end of the $\$ 32 M$ to $\$ 38 M$ range of anticipated outcomes), the adjusted pro forma EBITDA would be $\$ 229$ million, and our Funded Debt / adjusted pro forma annualized EBITDA ratio would be less than 5x. The Company is in ongoing negotiations regarding the Orianna portfolio, and accordingly the timing and terms of the transition of the Orianna portfolio may vary materially.

## EBITDA Reconciliation and Fixed Charge and Interest Coverage Ratio Calculation

Our adjusted EBITDA to total interest expense ratio and adjusted EBITDA to fixed charges as of December 31, 2017 were $4.3 x$ and $4.1 x$, respectively. Fixed charge coverage is the ratio determined by dividing EBITDA by our fixed charges. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA eliminates items such as acquisition costs and stock-based compensation expense and adds back certain non-cash expenses, if any, to EBITDA.

Fixed charges consist of interest expense, amortization of other non-cash interest charges, amortization of deferred financing costs and refinancing costs. EBITDA, adjusted EBITDA and interest expense ratio are non-GAAP measures. Below is the reconciliation of EBITDA to net income.

## Unaudited <br> (In thousands)

|  | Three Months Ended December 31, 2017 |  |
| :---: | :---: | :---: |
| Net income.. | \$ | 65,156 |
| Depreciation and amortization. |  | 75,323 |
| Depreciation - unconsolidated joint venture |  | 1,657 |
| Interest -net. |  | 50,491 |
| Income taxes. |  | 558 |
| EBITDA. | \$ | 193,185 |
| Deduct gain on assets sold - net. |  | $(46,421)$ |
| Deduct foreign currency gain. |  | (76) |
| Deduct one-time revenue. |  | (513) |
| Add back non-cash impairment on direct financing leases.. |  | 231 |
| Add back non-cash provision for uncollectible accounts.. |  | 913 |
| Add back non-cash provision for impairments on real estate properties.. |  | 63,460 |
| Add back stock-based compensation expense. |  | 3,862 |
| Adjusted EBITDA. | \$ | 214,641 |
| FIXED CHARGES |  |  |
| Interest expense....................................................................................................................... | \$ | 48,248 |
| Amortization of non-cash deferred financing charges. |  | 2,243 |
| Refinancing costs.. |  | - |
| Total interest expense.. | \$ | 50,491 |
| Add back: capitalized interest. |  | 2,124 |
| Less: refinancing charges.. |  | - |
| Total fixed charges............................................................................................................ | \$ | 52,615 |
| Adjusted EBITDA / total interest expense ratio..................................................................... |  | 4.3 x |
| Adjusted EBITDA / fixed charge coverage ratio...................................................................... |  | 4.1 x |

NOTE: Placed Orianna on a cash basis and recorded no revenue in the three months ended December 31, 2017. The Company is in ongoing negotiations regarding the Orianna portfolio, and accordingly the timing and terms of the transition of the Orianna portfolio may vary materially. The Company anticipates annual contractual rent will likely be in a range of $\mathbf{\$ 3 2 M}$ to $\$ \mathbf{3 8} \mathrm{M}$ once the Orianna transition is complete.

## Portfolio Metrics

EBITDARM Coverage: Represents EBITDARM of our operators, defined as earnings before interest, taxes, depreciation, amortization, Rent expense and management fees for the applicable period, divided by the total Rent paid to the Company by its operators during such period.

EBITDAR Coverage: Represents EBITDAR of our operators, defined as earnings before interest, taxes, depreciation, amortization, and Rent expense for the applicable period, divided by the total Rent paid to the Company by its operators during such period. Assumes a management fee of $4 \%$.

Portfolio Occupancy: Represents the average daily number of beds at the Company's properties that are occupied during the applicable period divided by the total number of total operating beds at the Company's properties that are available for use during the applicable period.

Property Type: ALF = assisted living facility; SNF = skilled nursing facility
Portfolio metrics and other statistics are not derived from Omega's financial statements but are operating statistics that the Company derives from reports that it receives from its operators pursuant to Omega's triple-net leases and mortgages. As a result, the Company's portfolio metrics typically lag its own financial statements by approximately one quarter. Portfolio metrics exclude assets held for sale, closed properties, properties under construction and, with certain exceptions for shorter periods, properties within 24 months of completion of construction.

Rent: Refers to the total monthly rent and mortgage interest due under all of the Company's lease and mortgage agreements as of the date specified, calculated based on the first full month following the specified date. Omega calculates "annualized rent" for properties during a period by utilizing the amount of rent under contract as of the last day of the period and assumes that amount of rent was received in respect of such property throughout the entire period.

## NON-GAAP Financial Measures

FFO: Funds from Operations (FFO), is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures.

AFFO: Adjusted FFO (AFFO) is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above.

FAD: Funds Available for Distribution (FAD) is calculated as AFFO less non-cash interest expense and non-cash revenue, such as straight-line rent.

A further discussion of the Non-GAAP Financial Measures defined above is provided on page 18 of this supplement.

